Myeloablative chemotherapy followed by transplantation of a T cell-depleted bone marrow graft from a partially mismatched related donor provides a potentially curative option for patients with leukemia and other disorders of hematopoiesis, although the patient is faced with a period of sustained immunodeficiency as well as pharmacologic immunosuppression as a result of prophylaxis against graft-versus-host disease. Thirty patients who received one to three antigen T celldepleted mismatched grafts were evaluated for immune reconstitution. The percentage and numbers of cells expressing lymphocyte subset antigens were determined by flow cytometry at 14, 28, 60, 100, 180, 270 and 365 days post-BMT and at 6 month intervals thereafter. Lymphocyte reconstitution was characterized by the early appearance of natural killer cells and a low percentage of both T and B cells. During the first year after BMT, the number of NK cells remained constant while T and B cells gradually returned to normal numbers and proportions. Response to the lymphocyte mitogen phytohemagglutinin returned to normal over the course of 2 years, while the response to concanavalin A was slightly depressed and the response to pokeweed mitogen became supranormal at about 1.5 years and continued to increase. These data suggest the need for long-term immunophenotypic monitoring as well as prolonged infection surveillance and prophylaxis. Keywords: bone marrow transplantation; T cell depletion; haploidentical donor; flow cytometry; immune reconstitution High-dose chemo/radiotherapy followed by allogeneic bone marrow transplantation (BMT) from a partially mismatched related donor (PMRD) provides a potentially curative treatment for patients who suffer from a variety of hematologic disorders where allogeneic BMT is the treatment of choice but who do not have a matched sibling donor (MSD).
Initially, total body irradiation (TBI) and intensive chemotherapy leave the patient with an ablated bone marrow, resulting in a lack of immunologic defense. Thus, in the immediate post-BMT period, the patient is susceptible to life-threatening viral, bacterial and fungal infections. 1 Severe combined (cellular and humoral) immunodeficiency continues after engraftment. In addition, pharmacologic immunosuppression to prevent or treat graft-versus-host disease (GVHD) interferes with the gradual recovery of normal immunity that occurs over a period ranging from one to several years. 2 Finally, late complications, such as chronic GVHD, can contribute to the prolongation of recovery. 3 Since almost all patients have access to BMT using family members who are at least one haplotype-matched with the patient, techniques have been sought to ensure prompt engraftment and reduce the risk of GVHD in this setting. 4, 5 In our center, sequential immunomodulation of the host and donor, including ex vivo T cell depletion of the marrow with a monoclonal antibody (MAb) directed against the ␣␤ T cell receptor, has been shown to result in an incidence of grade II-IV acute GVHD as low as 16% with 2-year survival of 55% in lower-risk patients. 6 The major goal in PMRD BMT is the successful manipulation of the developing recipient immune system to optimize a graft-versus-leukemia (GVL) effect while minimizing the severity of GVHD and avoiding life-threatening infections. Although expected to be significantly delayed, little is known about the repopulation of the peripheral blood and lymphoid organs and immune recovery following haploidentical PMRD BMT. A greater understanding of this process would facilitate directed cellular and pharmacologic therapy with the aim of enhancing engraftment, controlling GVHD, eradicating minimal residual disease, and protecting against infection. The value of immunophenotypic monitoring has been demonstrated in our laboratory and by others with respect to characterization and prediction of acute graft rejection, [7] [8] [9] prediction and monitoring of GVHD, [10] [11] [12] and monitoring of minimal residual disease post-BMT. 13 This study provides a comprehensive examination of the immunophenotypic and functional recovery of lymphocytes in the first 2 years following PMRD BMT.
Materials and methods

Clinical protocol
Following informed consent, patients were entered consecutively into a single-arm PMRD BMT trial. Sequential immunomodulation consisting of conditioning therapy, ex vivo TCD of the graft, and post-transplant combination immunosuppressive therapy (Figure 1 ) was administered as previously described. 5 Sufficient bone marrow was harvested to obtain a nucleated cell count of 4-6 × 10 8 cells/kg of recipient body weight prior to ex vivo manipulation. Grafts were TCD by ex vivo treatment with the T10B9:1A.31 (T10B9) MAb directed against the ␣␤ heterodimer of the T cell receptor and rabbit complement using methods described by Lee et al. 14 The residual T cells in the graft were quantitated immediately by flow cytometry and retrospectively by limiting dilution analysis. 15 The patients were followed indefinitely for relapse and survival. Patients with grade III-IV GVHD were excluded as the purpose of this study was to define 'normal' immune reconstitution in PMRD BMT patients. Immunophenotyping was performed prior to and at regular intervals following BMT. In an effort to improve engraftment, the total dose of TBI was increased from 1332 cGy (administered to the first 15 patients in this protocol) to 1400 cGy for the next four patients and then to 1500 cGy (administered to the subsequent 11 patients). Cyclosporine and prednisone were gradually tapered and discontinued in patients free of acute and/or chronic GVHD. TBI = total body irradiation administered twice daily via AP/PA fields with approximately 50% pulmonary transmission with lung shielding and electron beam boosting of the chest wall and testicles (ALL, biphenotypic) using an instantaneous dose rate of 13-22 cGy/min, and interfraction interval of approximately 8 h; VP-16 = etoposide administered once (omitted for nonmalignant disease); Ara-C = cytosine arabinoside administered twice daily × 6 doses; CTX = cyclophosphamide administered daily × 2 doses; MPD = methylprednisolone administered every 12 h × 4 doses; T10B9 = marrow graft T cell depleted with T10B9 and complement; CsA = cyclosporine started day −1 at 3 mg/kg constant infusion and maintained at levels between 100 and 200 as measured by the monoclonal antibody technique, switched to orally after day +21 and weaned gradually through the first year post-BMT; ATG = antithymocyte globulin administered daily × 12 doses on days +5 to +16. The steroid dose was tapered 10% weekly and switched to oral prednisone after day +21. . The lymphocyte population was identified and gated and analysis was performed using Lysis II and CellQuest software. Cell subpopulations were expressed as a percentage of the total lymphocyte population.
Flow cytometry
Mitogen assay
As a measure of immune function, the response to the mitogens concanavalin A (Con A), phytohemaglutinin (PHA-P), and pokeweed mitogen (PWM) (Sigma C-5275, L-9132 and L-9379; St Louis, MO, USA) was determined. Triplicate cultures containing 1 × 10 5 peripheral blood mononuclear cells (isolated on Ficoll-Hypaque gradients) were plated in 96-well flat bottom microtiter plates containing 0.2 ml of media (20% human AB serum/RPMI 1640). The cells were stimulated for 5 days with 0-20 g/well Con A or PHA-P and for 6 days with PWM at a 1/200 dilution. The proliferative response was measured by adding 0.5 Ci 3 H-thymidine/well approximately 12 h before harvesting the cells. Thymidine incorporation was determined on a standard scintillation counter (Packard Instruments, Meriden, CT, USA) and compared to the average response of two to three normal individuals included in each assay.
Data analysis and statistical procedures
Peripheral blood samples collected from 30 patients surviving at least 1 year were analyzed to determine absolute numbers and percentages of several markers as described above. These values were used to calculate the mean and standard error for the percentage of each cell subpopulation at each sampling time. Table 1 displays characteristics for the 30 patient-donor pairs. Acute leukemias accounted for 70% of diagnoses while chronic leukemia comprised 20% of the cases. Fortyseven percent of donor-recipient pairs were sex mismatched. Either the recipient or donor was CMV seropositive in 77% of the cases. Fifty-seven percent of patients were considered to be at high risk for treatment failure, based on disease status at time of transplant. A mismatch for two or three major HLA loci in the GVHD (donorrecipient) direction was present in 66% of patients, and 70% in the rejection (recipient-donor) direction. Successful engraftment was attained at a mean of 20 days post-BMT. The day of engraftment was defined as the first of 3 consecutive days on which the WBC count was 1000/l. All patients achieved stable hematopoietic chimerism. Only three patients developed grade II acute GVHD, and no patient had a higher grade. Table 2 shows characteristics of the 30 grafts. The median number of nucleated cells infused was 1.40 × 10 8 per kg, and the median T cell dose was 6.10 × 10 4 per kg. Grafts were T cell depleted to a median of 1.94 logs. Major lymphocyte subset recovery Lymphocyte recovery following PMRD BMT begins at approximately 14 days with the initial appearance of a donor-derived population of CD56 + natural killer (NK) cells which comprise greater than 90% of the lymphocyte population in the peripheral blood (Figure 2a and b) . CD3 + T lymphocytes begin to appear in some cases at day +14 and in all by day +28 following BMT. The proportion of NK cells remains predominant until at least +180 days following BMT, at which time the T lymphocyte population becomes predominant. B lymphocytes remain at very low levels until between day +100 and day +180 but are fully reconstituted by 1-1.5 years following BMT. 
Results
Patient characteristics
Graft characteristics
NK cell characteristics
Natural killer cells are defined as CD3 − CD56 + . As stated above, normal numbers of donor-derived NK cells are seen within the first month following BMT and they are the predominant cell population for the first 3-6 months. They were found to express the intermediate affinity IL-2 receptor p75 (CD122) as early as 14 days following BMT (Figure 3 ). The majority of these cells are also dim expressers of CD8. 
T lymphocyte characteristics
The predominant T cell during the first several weeks following PMRD BMT is CD3 + CD8 + and expresses the ␣␤ T cell receptor (Figure 5a and b) . CD3
+ CD4 + cells are present from day +14, but the CD4:CD8 T cell ratio usually does not become greater than 1.0 until the second year ( Figure 6 ). The CD3 + CD4 + population remains predominately CD45RA
− during the first 2 years following BMT in most patients, but CD3 +
CD4
+ CD45RA + cells have been seen in some patients who are 3 or more years post-BMT (data not shown). In addition, T cell reconstitution is not accompanied by increased T cell activation, as shown by the normal levels of class II expression (Figure 7) . T lymphocyte reconstitution in 11 patients revealed a predominance of CD3 + CD8 + CD57 + cytotoxic T cells which appear 60-100 days post-BMT and persist for about a year. These patients are usually delayed beyond 1.5 years in normalization of the CD4:CD8 ratio. In addition, 10 patients were found to have an increased (Ͼ 10%) proportion of ␥␦ + T cells in the peripheral blood at 60-270 days after transplantation. The TCR-␥␦ + cells were also found to coexpress CD57 but were negative for CD4 and CD8. TCR-␥␦ + cells in most patients returned to normal proportions and numbers within 1-1.5 years, although some patients have persisted with increased TCR-␥␦ + cells for up to 3 years following BMT.
Mitogen analysis
The peak response of patient peripheral blood mononuclear cells to the mitogens Con A, PHA-P and PWM, from day 60 to over 2 years post-transplant, is shown in Figure 8 . Generally, patients' cells are unable to respond to these mitogens until day 100. The Con A and PHA-P responses appear to be similar up to day 270, when the response is about 40% of normal. The Con A response continues to improve and is near normal at about 2 years. In contrast, the PHA-P response improves at a slower rate, and is about 70% of normal at 2 years. The PWM response recovery occurs much more rapidly, 89% by day 300, and continues to rise to significantly above normal at about 2 years.
Discussion
The transplantation of partially mismatched bone marrow from a related donor is not a common procedure, even though approximately 95% of patients needing allogeneic BMT would have an immediately available donor. HensleeDowney 16, 17 has extensively reviewed the risks and clinical outcome of PMRD BMT. A recent analysis from the International Bone Marrow Transplant Registry compared results following matched related and unrelated donor transplantation. While transplant-related complications and mortality were increased after all forms of alternative donor transplant, prolonged survival was achieved and a trend toward improved disease-free survival was seen in patients with advanced leukemia. 18 Methods developed in this decade show an encouraging decrease in transplant-related complications and improved outcome, particularly in patients transplanted earlier in their disease course. 6, 19 Nevertheless, an increased risk of lethal infection remains and causes concern regarding speed and completeness of immune recovery following alternative donor transplant. 20 Our study was undertaken to examine the immune reconstitution of patients who survived disease-free for at least 1 year following PMRD BMT and to compare the pattern of immune recovery in PMRD BMT patients with published data from other types of allogeneic BMT. Tracking immune reconstitution in patients with prolonged diseasefree survival should establish an expected reconstitution pattern which could be used to detect abnormal immune recovery. Since few studies of immune reconstitution have incorporated data from patients receiving PMRD grafts, these data are discussed in the context of existing literature which is primarily from patients receiving grafts from matched sibling donors (MSD). The first comprehensive immunophenotyping study of immune recovery involved four patients, three of whom received a TCD graft from a MSD and one who received a syngeneic graft followed by a short course of post-BMT immunosuppression with methotrexate in the allogeneic BMT patients. 21 This study established that phenotypic reconstitution of all major lymphocyte subtypes occurred within a year but that recovery was faster in the patient receiving the unmodified syngeneic graft. The study also described the early appearance of increased numbers of functional NK cells as well as early recovery of the CD4:CD8 ratio and the B cell population.
Lum 22 reviewed early studies of post-BMT immune recovery in patients following unmodified MSD BMT and made several observations including: (1) NK function is present within the first 30-60 days following BMT; (2) the absolute number of CD4 + cells remain low and the absolute number of CD8 + cells remain high for the first 3 months; and (3) cytotoxic function returns by post-BMT day 100 while more specialized functions of T and B cells may take more than a year to recover. Zintl et al, 23 in a study of nine patients receiving unmodified grafts with a short course of post-BMT immunosuppression consisting of methotrexate and prednisone, found that the T cell population did not reach the normal range until 3 months following BMT and the CD4:CD8 ratio did not normalize until at least 1 year. Keever et al 24 supplemented these data by comparing patients who received unmodified grafts with patients who received TCD grafts from matched sibling donors. In this study it was shown that neither the total number of T, B, or NK cells nor the CD4:CD8 ratio differed significantly between the two groups after the first 3 months following BMT, although the T cell mitogeneic response normalized more slowly in patients who received TCD grafts. The mean absolute number of T cells, NK cells, and B cells normalized between 7 and 9 months, 0.5 and 1 month and 2 and 3 months, respectively, for both study groups. Recovery of CD4
+ and/or CD8 + T cells has also been shown to occur more rapidly in recipients of non-T cell-depleted MSD grafts, as opposed to those who received T celldepleted marrow. 21 Immune recovery data from PMRD BMT have been reported by Smith et al, 25 who in a series of four patients found CD4:CD8 ratios as well as CD3 + cells to be below normal in the first 3 months following BMT in three of four patients receiving one to two antigen PMRD grafts. The post-BMT immunosuppression protocol consisted of ATG 20 mg/kg on alternating days until day +13, and methylprednisolone 1-2 mg/kg for 6 months. Kook et al, 26 in a study examining immunophenotypic reconstitution in 102 children who received either MUD or PMRD grafts, reported immunophenotypic data which are remarkably similar to this study, despite important differences in the patient populations, pre-BMT conditioning regimen, T cell depletion methodology, and post-BMT immunosuppression. Post-BMT immunosuppression was accomplished by the use of ATG 20 mg/kg on alternating days and prednisone, tapering at 6 months.
Cyclosporine was reserved for steroid-refractory GVHD. In Kook's study, T lymphocytes recovered at up to 18 months for CD3 +
CD8
+ cells to up to 3 years for CD3 + CD4
+ cells. T cell recovery in this study was very similar to ours, including the observation that an inverted CD4:CD8 ratio persists for 1 year post-BMT. B lymphocyte recovery was also depressed until 12-18 months post-BMT in both studies.
Notably, the pattern of NK recovery was very similar to our findings, despite the fact that T cell depletion was accomplished using anti-CD2 MAb and rabbit complement. Anti-CD2 will bind most T cells and subsets of NK cells, while OKT3 is specific for the T cell receptor. Our findings with respect to early NK recovery parallel data reported in TCD BMT from MSD, unrelated and PMRD transplants. [21] [22] [23] [24] [25] [26] [27] [28] The recovery of lymphocyte responses to the polyclonal mitogens Con A and PWM generally paralleled the immunophenotypic recovery, which normalized at 1-1.5 years. The response to PHA, however, was still depressed after 2 years. Interestingly, the PWM reactivity continued to rise well beyond normal (Figure 8 ). The significance of this finding is currently under investigation. Con A and PHA are T cell mitogens, PWM can stimulate both T and B cells, but requires T cells. One limitation of the traditional mitogen stimulation assay is the inability to determine which cell subtype(s) is/are responding to the mitogen. Recently, the expression of CD69 in a 4-h mitogenic assay has been shown to enable subtyping of lymphoid cells by identifying antigens which are expressed following mitogen stimulation. 29, 30 This technique may prove useful in correlating activation potential with immunophenotypic reconstitution.
This study was designed to determine the normal immune reconstitution pattern from patients receiving a T cell-depleted bone marrow transplant from a partially mis-matched related donor. Since the purpose of the study was to determine the immune recovery pattern in uncomplicated patients, those who experienced graft failure, overwhelming infections, disease relapse, or grade III-IV GVHD unresponsive to treatment were excluded from this report although data from such patients were obtained for later comparative analysis. It is hoped that the data from our study and others reported above will serve as a standard for evaluating infectious and immunologic complications post-PMRD BMT. Indeed, several related observations have been made from close monitoring of immune reconstitution, including characterization of acute graft rejection, 7, 8 identification of cell subsets which may predict a longer term survival, 31, 32 and early evaluation for minimal residual leukemia. 13 As immune modulation increases in importance in the management of patients following bone marrow transplantation, careful and comprehensive monitoring of immune reconstitution may serve as a guide for treatment design.
